Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Bylicki O, et al. Among authors: monnet i. Eur J Cancer. 2023 Apr;183:38-48. doi: 10.1016/j.ejca.2023.01.014. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801605 Free article. Clinical Trial.
[Unusual cause of severe alveolar hypoventilation].
Iglesias E, Fuhrman C, Chouaid C, Monnet I, Hagege H, Housset B. Iglesias E, et al. Among authors: monnet i. Rev Mal Respir. 2000 Feb;17(1):119-20. Rev Mal Respir. 2000. PMID: 10756566 French.
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C; GFPC 0504 Team. LeCaer H, et al. Br J Cancer. 2011 Oct 11;105(8):1123-30. doi: 10.1038/bjc.2011.331. Epub 2011 Sep 20. Br J Cancer. 2011. PMID: 21934690 Free PMC article. Clinical Trial.
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).
LeCaer H, Greillier L, Corre R, Jullian H, Crequit J, Falchero L, Dujon C, Berard H, Vergnenegre A, Chouaid C; GFPC 0505 Team. LeCaer H, et al. Lung Cancer. 2012 Jul;77(1):97-103. doi: 10.1016/j.lungcan.2012.02.004. Epub 2012 Mar 8. Lung Cancer. 2012. PMID: 22405570 Clinical Trial.
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C, Le Caer H, Locher C, Dujon C, Thomas P, Auliac JB, Monnet I, Vergnenegre A; GFPC 0504 Team. Chouaid C, et al. Among authors: monnet i. BMC Cancer. 2012 Jul 20;12:301. doi: 10.1186/1471-2407-12-301. BMC Cancer. 2012. PMID: 22817667 Free PMC article. Clinical Trial.
200 results